Volume 31, Number 7—July 2025
EIN Letter
Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024
Kaitlin Benedict
, Alexander Jordan, Jeremy A.W. Gold, Dallas J. Smith, Tom Chiller, Ian Hennessee, Philip M. Polgreen, and Susan E. Beekmann
, Alexander Jordan, Jeremy A.W. Gold, Dallas J. Smith, Tom Chiller, Ian Hennessee, Philip M. Polgreen, and Susan E. Beekmann
Table 2
Cryptococcal antigen blood test use for patients with advanced HIV, reported by 215 US infectious disease providers in Emerging Infections Network survey of screening for cryptococcal antigenemia, United States, 2024*
| Characteristic | CD4 count, no. (%)† |
|
|---|---|---|
| <100 cells/mm3 | <200 cells/mm3 | |
| Newly initiating ART | n = 171 | n = 166 |
| Never | 23 (13) | 34 (20) |
| Rarely | 22 (13) | 43 (26) |
| Sometimes | 19 (11) | 34 (20) |
| Often | 27 (16) | 19 (11) |
| Always |
80 (47) |
36 (22) |
| Reinitiating ART | n = 168 | n = 160 |
| Never | 35 (21) | 48 (30) |
| Rarely | 28 (17) | 44 (28) |
| Sometimes | 47 (28) | 41 (26) |
| Often | 20 (12) | 13 (8) |
| Always |
38 (23) |
14 (9) |
| Experiencing ART failure | n = 166 | n = 161 |
| Never | 44 (27) | 57 (35) |
| Rarely | 37 (22) | 47 (29) |
| Sometimes | 51 (31) | 44 (27) |
| Often | 20 (12) | 8 (5) |
| Always |
14 (8) |
5 (3) |
| Seriously ill‡ | n = 176 | n = 168 |
| Never | 8 (5) | 11 (7) |
| Rarely | 5 (3) | 16 (10) |
| Sometimes | 27 (15) | 27 (16) |
| Often | 43 (24) | 38 (23) |
| Always | 93 (53) | 76 (45) |
*ART, antiretroviral therapy. †Among respondents who answered each question. ‡Regardless of ART status.
Page created: May 15, 2025
Page updated: June 25, 2025
Page reviewed: June 25, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.